Nomura Securities Downgrades Valeant Pharmaceuticals (VRX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St inches lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil slides on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
- Ovintiv adds 41,000 acres in Permian and Montney deals
Valeant Pharma (VRX) Price Target Lowered to $45 at TD Securities
March 16, 2016 11:16 AM EDTTD Securities earlier maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) and lowered its price target to $45.00 (from $110.00). The change follows updated guidance announced yesterday.
Analyst Lennox Gibbs said, "This latest revision layers on to an already protracted decline in... More
Valeant (VRX) PT Cut to $53 at Jefferies
March 16, 2016 11:05 AM EDTJefferies analyst David Steinberg lowered his price target on Valeant Pharmaceuticals (NYSE: VRX) to $53.00 (from $106.00) but maintained his Buy rating after shares were pummeled yesterday on weak guidance.
Steinberg commented, "VRXs highly anticipated FY16 guidance was much lighter than expected as key... More
Valeant Pharma (VRX) Adds to Gains on Rumor
March 16, 2016 10:12 AM EDTValeant Pharma (NYSE: VRX) is adding to early gains on a vague rumor Carl Icahn could become involved in the name. Shares are up 3.1%.
For what its worth, Icahn rumors are almost 100% wrong and the last thing the stock needs is another hedge fund manger involved.
... MoreValeant Pharma (VRX) Sees Early Upside after Massive Beating
March 16, 2016 9:48 AM EDTAfter staring lower, Valeant Pharma (NYSE: VRX) is up 2.7% today after getting annihilated to the tune of 51% on Tuesday.
... MoreValeant (VRX) PT Cut to $40 at Canaccord Genuity
March 16, 2016 9:40 AM EDTCanaccord Genuity analyst Neil Maruok reiterated a Hold rating and lowered his price target on Valeant Pharmaceuticals (NYSE: VRX) to $40.00 (from $75.00).
Maruok commented, "guidance was even lower than our base-case scenario and we believe has begun to erode investor confidence in Valeants underlying business. We believe that the implementation of the partnership with Walgreens,... More
Valeant (VRX) Default 'Unlikely', Says Rodman & Renshaw
March 16, 2016 7:43 AM EDTRodman & Renshaw reiterated a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with a modified price target of $118.00 (from $150.00). The change follows soft guidance issued yesterday. Analyst Raghurum Selvaraju noted that the stock's plunge was motivated by fear of default, which he sees as unlikely.
Selvaraju explained, "From our perspective, the main hurdle at this juncture for Valeant is the lack of credibility... More
